1. Home
  2. URGN vs AIV Comparison

URGN vs AIV Comparison

Compare URGN & AIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$21.96

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Apartment Investment and Management Company

AIV

Apartment Investment and Management Company

HOLD

Current Price

$5.80

Market Cap

1.2B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
URGN
AIV
Founded
2004
1975
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
2017
1994

Fundamental Metrics

Financial Performance
Metric
URGN
AIV
Price
$21.96
$5.80
Analyst Decision
Strong Buy
Buy
Analyst Count
8
1
Target Price
$28.50
$10.00
AVG Volume (30 Days)
998.4K
1.5M
Earning Date
11-06-2025
11-10-2025
Dividend Yield
N/A
48.88%
EPS Growth
N/A
N/A
EPS
N/A
1.72
Revenue
$96,516,000.00
$210,889,000.00
Revenue This Year
$27.96
$6.96
Revenue Next Year
$123.02
N/A
P/E Ratio
N/A
$3.72
Revenue Growth
8.00
39.67
52 Week Low
$3.42
$5.24
52 Week High
$30.00
$9.29

Technical Indicators

Market Signals
Indicator
URGN
AIV
Relative Strength Index (RSI) 42.19 55.11
Support Level $21.74 $5.58
Resistance Level $30.00 $5.62
Average True Range (ATR) 1.56 0.07
MACD -0.72 0.05
Stochastic Oscillator 3.15 98.00

Price Performance

Historical Comparison
URGN
AIV

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

About AIV Apartment Investment and Management Company

Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment; Operating, and Other. Development and Redevelopment segment consists of properties that are under construction or have not achieved stabilization, as well as land held for development. Operating segment includes 20 residential apartment communities with 5,243 apartment homes that have achieved a stabilized level of operations. Other segment includes The Benson Hotel, company's only hotel. Majority of revenue is gained from Operating Segment.

Share on Social Networks: